Skip to main content
Premium Trial:

Request an Annual Quote

For Fetal Hemoglobin

A study using a CRISPR-based approach to treat sickle-cell disease has reported promising results, the Associated Press reports.

Last year, Vertex Pharmaceuticals and CRISPR Therapeutics launched a study in which doctors isolated cells from patients' bone marrow and edited them to produce the fetal version of hemoglobin, before re-introducing the cells to patients. About a year after treatment, study participant Victoria Gray told NPR she was doing well and was producing fetal hemoglobin.

The AP notes additional data from the study have now been presented at the American Society of Hematology conference and published in the New England Journal of Medicine. In NEJM, Sarah Cannon Center for Blood Cancer's Haydar Frangoul and his colleagues report that two patients from their study, one with sickle-cell disease and one with β-thalassemia, have had sustained increases in fetal hemoglobin levels. Frangoul and his colleagues note they have since treated a further eight patients with similar results.

"The preliminary results are extremely encouraging," Frangoul tells the AP.

In a separate NEJM paper, researchers from Harvard Medical School report on their study of six patients with severe sickle cell disease who they treated using a shRNA targeting the same gene. They too report that their patients had increased fetal hemoglobin levels.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.